Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques E Rossouw

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Menopause (New York, N.Y.)|October 21, 2025
Baseline use of aspirin or statins with oral estrogen and progestogens to prevent incident arterial or venous thrombotic events: a secondary analysis of the Women's Health Initiative trialJohn W Davis, Aaron K Aragaki, Laura B Harrington, et al.
Genome Medicine|June 28, 2011
Genetic variants in the MRPS30 region and postmenopausal breast cancer riskYing Huang, Dennis G Ballinger, James Y Dai, et al.
Genome Medicine|March 14, 2012
Genetic variants in the MRPS30 region and postmenopausal breast cancer riskYing Huang, Dennis G Ballinger, James Y Dai, et al.
The American Journal of Cardiology|May 21, 2008
Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary eventsPaul F Bray, Joseph C Larson, Andrea Z Lacroix, et al.
Obstetrics and Gynecology|February 27, 2025
Long-Term Changes to Cardiovascular Biomarkers After Hormone Therapy in the Women's Health Initiative Hormone Therapy Clinical TrialsMatthew Nudy, Aaron K Aragaki, Xuezhi Jiang, et al.
Circulation|August 31, 2012
Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapyJacques E Rossouw, Ross L Prentice, JoAnn E Manson, et al.
Menopause (New York, N.Y.)|September 19, 2013
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational StudyChrisandra L Shufelt, C Noel Bairey Merz, Ross L Prentice, et al.
American Journal of Public Health|October 19, 2013
Women's health initiative view of estrogen avoidance and all-cause mortalityRoss L Prentice, Joann E Manson, Garnet L Anderson, et al.
American Journal of Epidemiology|April 22, 2020
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy TrialsRoss L Prentice, Aaron K Aragaki, Rowan T Chlebowski, et al.
Journal of Hypertension|July 4, 2014
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trialsDaichi Shimbo, Lu Wang, Michael J Lamonte, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Menopause (New York, N.Y.)|October 21, 2025
Baseline use of aspirin or statins with oral estrogen and progestogens to prevent incident arterial or venous thrombotic events: a secondary analysis of the Women's Health Initiative trialJohn W Davis, Aaron K Aragaki, Laura B Harrington, et al.
Genome Medicine|June 28, 2011
Genetic variants in the MRPS30 region and postmenopausal breast cancer riskYing Huang, Dennis G Ballinger, James Y Dai, et al.
Genome Medicine|March 14, 2012
Genetic variants in the MRPS30 region and postmenopausal breast cancer riskYing Huang, Dennis G Ballinger, James Y Dai, et al.
The American Journal of Cardiology|May 21, 2008
Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary eventsPaul F Bray, Joseph C Larson, Andrea Z Lacroix, et al.
Obstetrics and Gynecology|February 27, 2025
Long-Term Changes to Cardiovascular Biomarkers After Hormone Therapy in the Women's Health Initiative Hormone Therapy Clinical TrialsMatthew Nudy, Aaron K Aragaki, Xuezhi Jiang, et al.
Circulation|August 31, 2012
Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapyJacques E Rossouw, Ross L Prentice, JoAnn E Manson, et al.
Menopause (New York, N.Y.)|September 19, 2013
Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational StudyChrisandra L Shufelt, C Noel Bairey Merz, Ross L Prentice, et al.
American Journal of Public Health|October 19, 2013
Women's health initiative view of estrogen avoidance and all-cause mortalityRoss L Prentice, Joann E Manson, Garnet L Anderson, et al.
American Journal of Epidemiology|April 22, 2020
Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy TrialsRoss L Prentice, Aaron K Aragaki, Rowan T Chlebowski, et al.
Journal of Hypertension|July 4, 2014
The effect of hormone therapy on mean blood pressure and visit-to-visit blood pressure variability in postmenopausal women: results from the Women's Health Initiative randomized controlled trialsDaichi Shimbo, Lu Wang, Michael J Lamonte, et al.
Pageof 10